Non-small cell lung cancer (NSCLC) is one of the most threatening malignancies to human
health and life. In most cases, patients with NSCLC are already at an advanced stage when …

Extracellular vesicles (EVs), including exosomes, play a crucial role in intercellular
communication and have emerged as important mediators in the development and …

Introduction Non-small cell lung cancer (NSCLC) is the leading cause of cancer incidence
and mortality worldwide. Neoadjuvant chemo-immunotherapy has led to clinical benefits in …

In around 30% of patients, non-small cell lung cancer is diagnosed at an advanced but
resectable stage. Adding systemic therapy has shown clear benefit over surgery alone in …

Background Non-small cell lung cancer (NSCLC) has a high mortality rate and poor
prognosis. The early detection of high-risk patients is essential to improve patient prognosis …

Background and Objectives: Although perioperative immunotherapy is implemented as a
standard of care for resected non-small cell lung cancer (NSCLC), there is unmet need for …

We are proud and happy to present this Special Issue, a follow-up to the third joint meeting
on lung cancer of the FHU OncoAge (University Côte d'Azur, Nice, France) and the …

Background Pathologic tumor response and changes in the tumor microenvironment (TME)
following immunotherapy serve as surrogate markers to predict clinical outcomes in patients …

The therapeutic efficacy of neoadjuvant immunotherapy combined with chemotherapy (Io+
Chemo) is superior than chemotherapy alone (Chemo). However, the mechanism of Io+ …